

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

David Rowlands et al

Confirmation No. 3251

Application No.:

10/520,550

PCT Application No.:

PCT/GB03/02937

I.A. Filing Date:

July 7, 2003

For:

Use of Hepatitis C Virus (HCV) P7 Protein

Mail Stop PCT

May 17, 2006

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted

Shawna Cannon Lemon Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A. P. O. Box 37428, Raleigh, NC 27627

Telephone: (919) 854-1400 Facsimile: (919) 854-1401 Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number: EV 854925350 US Date of Deposit: May 17, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed Name of Person Signing Certificate: Sarah E. Abraham

MAG 17, 2006

Date of Signature

Substitute form 1449A/F	то	Complete if Known		
		Application Number	10/520,550	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date		
		First Named Inventor	David Rowlands	
		Group Art Unit		
(use as many sheets as necessary)		Examiner Name		
Sheet 1 of 1		Attorney Docket Number	9052-212	

U.S. PATENTS AND PATENT PUBLICATIONS						
Examiner Cite I	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
		Number	Kind Code (if known)	Document	MM-DD-YYYY	
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
muais	No.	Office	Number	Kind Code (if known)	_ Document	Cited Document MM-DD-YYYY	
	1.	WO	98 19670	Α	Najarian, Thomas	05-14-1998	
	2.	WO	98 21338	Α	US Health	05-22-1998	
*.					ę.		

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	3.	GRIFFIN, S.D.C., et al. "The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine," <u>FEBS Letters</u> , (2003) pp 34-38, 535:1-3, Elsevier Science Publishers, Amsterdam, NL	
	4.		
	5.		
	6.		
	7.		

Examiner Signature Date Cons	sidered